LCM
FENC icon

Legato Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Legato Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,121
Closed -$635K – 584
2024
Q1 		$635K Buy
+57,121
New +$574K 0.08% 385

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Legato Capital Management's FENC Position: Q2 2024 in Review

Legato Capital Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2024, closing a stake of 57,121 shares — an estimated $635K sold.

Legato Capital Management first reported a position in FENC in Q1 2024 and held it in 1 quarter. The position peaked at $635K in Q1 2024. 64 funds tracked by Wall St. Rank hold FENC as of Q2 2024.

  • Legato Capital Management reported no remaining Fennec Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Legato Capital Management sold 57,121 Fennec Pharmaceuticals shares in Q2 2024, an estimated $635K.
  • Legato Capital Management first reported a position in Fennec Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Legato Capital Management's Fennec Pharmaceuticals position peaked at $635K in Q1 2024.
  • 64 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2024.

Based on Legato Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.